U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H26N2O4
Molecular Weight 370.4421
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SAMIDORPHAN

SMILES

NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]5(CC(=O)CC[C@@]35O)C2=C1O

InChI

InChIKey=RYIDHLJADOKWFM-MAODMQOUSA-N
InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1

HIDE SMILES / InChI
Molecular Formula C21H26N2O4
Molecular Weight 370.4421
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Samidorphan was developed as a sublingually bioavailable µ-opioid receptor antagonist. This drug participated in clinical trials for the treatment of Schizophrenia, Alcohol Dependence, and Binge Eating Disorder. The oral dose pharmacokinetics, safety, and tolerability of samidorphan were evaluated in phase II double blind, placebo-controlled, randomized studies in healthy adults. In addition, the combination of samidorphan (SAM) with buprenorphine (BUP) was studied in phase III clinical trial in patients with major depressive disorder (MDM). It was shown that the long-term treatment did not reveal any new safety findings and confirmed that the risk of abuse and dependence with BUP/SAM was low.

Approval Year

2021
470
PubMed

PubMed

TitleDatePubMed
Evaluation of samidorphan, a μ-opioid antagonist, in a drug discrimination assay in rats.
2018 Aug
Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence.
2018 Oct
Patents

Patents

08263807
6
08563572
6
20060111384
2
20070238748
2
20090197905
5

Sample Use Guides

In Vivo Use Guide
Samidorphan (Low Dose). Tablets taken once daily
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:45:57 UTC 2023
Edited
by admin
on Sat Dec 16 01:45:57 UTC 2023
Record UNII
7W2581Z5L8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SAMIDORPHAN
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
ALKS-5461 COMPONENT SAMIDORPHAN
Code English
samidorphan [INN]
Common Name English
Samidorphan [WHO-DD]
Common Name English
ALKS-33
Code English
MORPHINAN-3-CARBOXAMIDE, 17-(CYCLOPROPYLMETHYL)-4,14-DIHYDROXY-6-OXO-
Systematic Name English
SAMIDORPHAN [USAN]
Common Name English
RDC-0313
Code English
17-(Cyclopropylmethyl)-4,14-dihydroxy-6-oxomorphinan-3-carboxamide
Systematic Name English
RDC-0313-00
Code English
ALKS 33
Code English
Classification Tree Code System Code
NCI_THESAURUS C681
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C152293
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
SMS_ID
100000164891
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
PUBCHEM
11667832
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
EPA CompTox
DTXSID401030402
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
ChEMBL
CHEMBL426084
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
FDA UNII
7W2581Z5L8
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
EVMPD
SUB179484
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
CAS
852626-89-2
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
INN
9515
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
RXCUI
2559612
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
DRUG BANK
DB12543
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
USAN
XX-137
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
DAILYMED
7W2581Z5L8
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
WIKIPEDIA
SAMIDORPHAN
Created by admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
PRIMARY
Related Record Type Details
Structure of SAMIDORPHAN L-MALATE
SALT/SOLVATE -> PARENT
KAPPA-TYPE OPIOID RECEPTOR
TARGET->PARTIAL AGONIST
weak partial agonist
BINDING
Ki
MU-TYPE OPIOID RECEPTOR
TARGET -> INHIBITOR
could have very weak partial agonist activity
BINDING
Ki
DELTA-TYPE OPIOID RECEPTOR
TARGET->PARTIAL AGONIST
BINDING
Ki
Related Record Type Details
Structure of SAMIDORPHAN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966